-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
December 2021
-
Novel RET Inhibitors Promising in Chinese Patients with RET-fusion Positive NSCLC
The results of two studies presented at the 2021 World Conference on Lung Cancer—LIBRETTO-321 and ARROW—indicate that the selective RET inhibitors selpercatinib and pralsetinib are promising treatment options for patients in China with RET-fusion positive NSCLC. According to the studies’ discussant Shengxiang (Henry) Ren, MD, PhD, of Shanghai Pulmonary Hospital, Tongji University, Shanghai, China, both…
-
Second-Line Platinum-Doublet Regimens Reasonable in SCLC
Use of platinum-doublet chemotherapy regimen as second-line treatment for patients with relapsed small-cell lung cancer (SCLC) was a reasonable option compared with nonplatinum-based regimens, according to data from a meta-analysis presented at the WCLC Congress 2021. “Optimal second-line chemotherapy for patients with relapsed SCLC remains unclear,” according to study presenter Takashi Sato, MD, PhD, of…
-
Multifaceted Initiative Launches Aimed at Reducing Lung Cancer Deaths 25% by 2030
The Baptist Cancer Center in Memphis, Tennessee, has launched a new initiative that comprises seven components that will address prevention, diagnosis, and treatment of lung cancer through smoking cessation, low-dose CT screening, algorithmic management of incidentally detected lung nodules, multidisciplinary decision-making and care, high-quality surgical care, high-quality pathologic evaluation (including biomarker testing), and expanded access…
-
Increasing Adherence to CT Lung Cancer Screening Programs
Two large-scale, randomized controlled trials—the U.S. National Lung Screening Trial (NLST; n = 53,454) and the Dutch–Belgian Randomized Lung Cancer Screening Trial (NELSON; n = 15,792)—have demonstrated that lung cancer screening (LCS) with low-dose CT substantially reduces lung cancer mortality in a high-risk population.1,2 Despite the conclusive evidence for the effectiveness of LCS, national data…
-
COVID-19 and Lung Cancer
Data from multiple groups1,2 have shown the significant impact of COVID-19 infection among patients with malignancies, leading to high overall morbidity and mortality; this includes our own institution,3 which saw numerous cases of COVID-19 very early in the pandemic. Lung cancer stood out as the cancer (along with hematological malignancies) most significantly impacted by this…
-
Determining Adjuvant Therapy Through Recurrence Prediction: New Investigations
Amid growing interest in validating relapse-prediction models, team links high-grade histology, even if not predominant, with worse outcomes in EGFR-mutated stage 1 NSCLC.